23andMe, MondoBiotech Collaborate to Study Genetic Risk for Rare Diseases
February 04, 2009
23andMe, MondoBiotech Collaborate to Study Genetic Risk for Rare Diseases
Details of the deal are sparse, but the partners said they hope their research will lead to the development of genetic tests that can gauge patients’ predisposition to rare diseases and help target individuals most likely to respond to drugs made by MondoBiotech.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Navigenics Launches Cheaper Annual Genomic Service; Will Doctors Bite?
February 4, 2009 / Pharmacogenomics Reporter - Short Reads
February 3, 2009 / In Sequence - Moving Target: CNVs in Disease
April 29, 2009 / Genome Technology - NY State Health Department Regulating DTC Genomics Firms as Labs; No More 'Spit Parties'
March 18, 2009 / Pharmacogenomics Reporter - In Picking Up Affy's CLIA Lab is Navigenics Inviting More Regulatory Woes?
March 18, 2009 / Pharmacogenomics Reporter